Management of Hyperactive Delirium in the Pediatric Intensive Care Unit: Case Series of Three Young Children

Anna O Jesus1, Lotte Jones2, Rebecca Linares3

  • 1Division of Neurodevelopmental and Behavioral Pediatrics, University of Virginia, Charlottesville, Virginia, United States.

Insights

Pediatric intensive care unit (ICU) delirium can be serious. Atypical antipsychotics, though not FDA-approved for this use, were successfully used in short courses to treat three children with severe hyperactive delirium.

Area of Science:

  • Pediatric critical care medicine
  • Neuroscience
  • Pharmacology

Background:

  • Children in the intensive care unit (ICU) face a high risk of delirium due to illness, treatments, and the ICU environment.
  • Delirium in critically ill children can lead to severe complications.
  • Non-pharmacologic interventions are the first line of treatment, but may be insufficient.

Observation:

  • Three pediatric patients in the ICU presented with hyperactive delirium.
  • These patients were at risk for life-threatening complications due to their delirium.
  • Standard treatments for delirium were considered unsuccessful or insufficient for these cases.

Findings:

  • A short course of atypical antipsychotic medications was administered to the three pediatric patients.
  • The atypical antipsychotics were effective in treating the hyperactive ICU delirium.
  • No significant adverse side effects were reported during the short treatment courses.

Implications:

  • Atypical antipsychotics may be a viable treatment option for severe pediatric ICU delirium when other methods fail.
  • Further research is warranted to establish the safety and efficacy of atypical antipsychotics for pediatric delirium.
  • This case report highlights a potential therapeutic strategy for a challenging clinical problem in pediatric critical care.

Related Concept Videos

Attention-Deficit/Hyperactivity Disorder01:30

Attention-Deficit/Hyperactivity Disorder

Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by persistent inattention, hyperactivity, and impulsivity. It affects approximately 5-8% of children globally, with around 60-70% of cases persisting into adulthood. ADHD has significant implications for educational attainment, social interactions, and occupational success.
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings....
650
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
148
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
130
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
173
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
170
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
194